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Background: Sutherlandia frutescens (S. frutescens) is a shrub with attractive flowers 
used traditionally by in South African to treat a variety of health conditions. Its anti-
cancer activity has been reported in a number of cancers, and accordingly, this study 
was designed to investigate the cytotoxic activity and apoptosis-inducing effects of S. 
frutescens in neuroblastoma cells, a type of childhood cancer and a leading cause of 
death in children. Method: In this study, the effect of S. frutescens on cell viability and 
survival of SKNBE(2) and SHSY5Y neuroblastoma cells was determined using the 
MMT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide) cell viability 
assay and clonogenic assay respectively. Furthermore, flow cytometry was used to 
investigate the accumulation of intracellular reactive oxygen species (ROS) as well as 
loss of mitochondrial membrane potential (MMP). Caspase-9 activation was also used 
to detect apoptosis in these cells. Results: The results from this study show that 
exposure of S. frutescens to SKNBE(2) and SHSY5Y cells led to the inhibition of cell 
viability and survival and also induced apoptosis, increased intracellular accumulation 
of ROS and triggered a loss of MMP in these cells. Conclusion: Findings from this 
study validate folkloric claims on S. frutescens and demonstrate that this plant might 
serve as a potential anti-cancer agent in neuroblastoma cells, thus providing the 
rationale for further investigations into the bioactive components eliciting these 
activities. 
 
© Copyright 2018 African Association of Physiological Sciences -ISSN: 2315-9987. All rights reserved
 
INTRODUCTION   
Childhood cancer remains the leading cause of disease-
related death in children (van der Pal et al., 2010). 
Neuroblastoma, an embryonal cancer of the sympathetic 
nervous system, often occurs in young children 
(Howman-Giles et al., 2007). Clinically, children with 
neuroblastoma are designated as high-risk patients and 
conventional treatment involves a co-ordinated 
sequence of chemotherapy, surgery, and radiation 
(Pearson et al., 2008). 
 
Although there have been significant improvement in the 
outcomes of neuroblastoma patients due to intensified 
chemotherapy, many children with high-risk 
neuroblastomas sometimes develop complications, 
including hearing loss, cardiac dysfunction, infertility, 
and second malignancies (Zage et al., 2008). Therefore, 
more effective and less toxic therapeutic strategies need 
to be developed, including selective and efficient 
targeting of tumour cells to improve survival. 
More than 80% of the world’s population make use of 
complementary and alternative medicines which include 
herbalism and botanical medicines (Mainardi et al., 
2009, Robinson and Zhang, 2011). Plant and plant-
derived products have been reported to serve as a 
template for the discovery of new drugs due to their 
content of active ingredients which have the same 
molecular targets as pharmaceutical drugs (Pan et al., 
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2013, Yuan et al., 2016, Ahn, 2017). Many drugs used 
in cancer chemotherapy including vincristine, 
irinotecan, etoposide and paclitaxel, are classic 
examples of medicinal plant-derived compounds 
(Balunas and Kinghorn, 2005, Nobili et al., 2009). Thus, 
herbal and botanical medicines represent an enormous 
medicinal resource at a fraction of the cost of 
conventional medicine. Due to the numerous gains of 
plant and plant-derived compounds in cancer research, 
S. frutescens has been selected as the plant of study in 
this research.  
S. frutescens (unwele in Zulu; kankerbos in Afrikaans; 
cancer bush in English), a member of the pea family, is 
a shrub with attractive flowers used traditionally by 
South Africans to treat a variety of health conditions. 
The medicinal use probably originated with the Khoi and 
Nama people of South Africa; who used the plant 
decoctions externally to wash wounds and internally for 
fevers and a variety of other ailments. Also, it is used as 
an old Cape remedy for stomach problems and internal 
cancers (Van Wyk and Gericke, 2000).  
Previous studies have evaluated the effects of S. 
frutescens on several cancer cell lines. The ethanolic 
extract has been reported to have a concentration-
dependent anti-proliferative effect on MCF7 and MDA-
MB-468 (breast cancer cells) as well as Jurkat leukemic 
cells and HL60 (Tai et al., 2004, Stander et al., 2007). 
The ethanolic extract was also demonstrated to induce 
an S-phase cell cycle arrest, apoptosis and autophagy in 
cultured breast adenocarcinoma cells. The aqueous 
extract of S. frutescens was reported to inhibit the growth 
of MCF-7 cells and induce cytotoxicity in cervical 
carcinoma (Caski) and Chinese hamster ovary (CHO) 
cells (Chinkwo, 2005, Steenkamp and Gouws, 2006). 
Recently, S. frutescens was reported to modulate 
apoptosis induction in colon cancer cells via the 
phosphatidylinositol 3-kinase pathway as well as cause 
caspase-independent cell death in melanoma cells 
(Leisching et al., 2015, van der Walt et al., 2016). S. 
frutescens has been shown in humans to be safe and to 
have non-toxic or deleterious side effects (Johnson et al., 
2007). Therefore, the overall aim of this study was to 
evaluate the cytotoxic and apoptosis-inducing effects of 
S. frutescens in SK-N-BE (2) and SHSY5Y 
neuroblastoma cells, with a view to understanding its 
benefits as a potential anticancer agent.  
 
MATERIALS AND METHODS 
Preparation of S. frutescens aqueous extract 
Powdered dry leaves of S. frutescens R. BR. (variety 
Incana E. Mey.) [family: Fabaceae] were purchased 
from the suppliers Big Tree Health Products (Fish Hoek, 
South Africa) and 1 kg of the powdered preparation was 
soaked in boiling water and left overnight for extraction. 
The resultant extract was filtered with Whatman filter 
paper and the filtrate was evaporated in a freeze-dryer to 
obtain a dried powder product which was stored away at 
-20°C until needed. Aliquot portions of the product were 
weighed and dissolved in phosphate buffered saline 
(PBS, Lonza Group Ltd., Verviers, Belgium) to give a 
stock solution from which dilutions were made in media 
for treatment of cells on each day of the experiment. 
 
Cell lines and culture conditions. 
The human malignant neuroblastoma cell lines 
SKNBE(2) and SHSY5Y as well as the non-cancerous 
KMST6 fibroblast cells were cultured in monolayer 
using Dulbeco Modified Eagles Medium (DMEM, 
Lonza Group Ltd., Verviers, Belgium) supplemented 
with 10% foetal bovine serum (FBS, Gibco, Life 
Technologies Corporation, Paisley, UK) and 1% 100 
U/mL penicillin and 100 μg/mL (Lonza Group Ltd. 
Verviers, Belgium). Cells were grown at 37°C, in a 
humidified atmosphere consisting of 5% CO2 and 95% 
air, and the culture medium was routinely replaced every 
two to three days and the cells were sub-cultured using a 
solution of 0.25 % trypsin EDTA (Lonza Group Ltd., 
Verviers, Belgium) when 80% confluency was attained. 
 
Measurement of cell viability 
Cell viability was determined using the 3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide 
(MTT) assay kit (Roche, USA) following the 
manufacturer’s protocol. Briefly, SKNBE(2) and 
SHSY5Y cells were plated in 96-well cell culture plates 
at a cell density of 2500 and 5000 cells respectively per 
well and incubated overnight for 24 hours to allow the 
cells to attach. The medium was thereafter replaced with 
fresh medium containing increasing concentrations of S. 
frutescens (0 to 5 mg/ml) for 48 hours and untreated cells 
served as control. After 48 hours incubation, 10 μl of the 
MTT solution (5 mg/ml) was added to each well and the 
cells were incubated for an additional 4 hours at 37°C, 
followed by the addition of 100 μl of the solubilisation 
buffer (10% SDS in 0.01 M HCl). Plates were then left 
overnight at 37°C and absorbance of each well was read 
at 570 nm using a BMG Labtech Omega® POLARStar 
multimodal plate reader. The percentage cell viability 




The concentration required to kill 50% of the cells (IC50) 
was determined via a survival curve using GraphPad 
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Prism 6 software (GraphPad software, San Diego, CA, 
USA) and all experiments were conducted in triplicates. 
 
Clonogenic assay 
The clonogenic assay was conducted to determine the 
impact of extract treatment on cell survival. This assay 
assesses the ability of single cells to divide and form 
colonies (a colony consists of 50 cells) after being 
treated with anticancer agents. Briefly, cells were plated 
in 60 mm dishes and allowed to grow overnight before 
exposure to two different concentrations of the extract 
(half the IC50 and IC50) for 24 hours. After treatments, 
cells were harvested and re-plated at a density of 500 
cells per dish in 35 mm dishes and were allowed to grow 
over a period of fourteen days to form colonies. At the 
termination of the experiment, formed colonies were 
fixed with a solution of methanol and glacial acetic acid 
(3:1) and stained with 0.5% crystal violet stain. Images 
of the dishes were taken and areas covered by colonies 
were calculated using Image J software and expressed as 
a percentage of the control which was set at hundred 
percent. 
 
Detection of apoptosis 
The Caspase-9 ApoTarget® colorimetric assay kit 
(Invitrogen, Life Technologies, USA) was used to 
determine Caspase-9 activity following manufacturer 
instructions. Briefly, cells were seeded in 60 mm dishes 
and allowed to settle overnight before treatment with the 
IC50 of S. frutescens for 48 hours. Cells were harvested 
and lysed for 10 minutes in cold lysis buffer and 
centrifuged at 10 000 x g for 1 minute. The supernatant was 
thereafter transferred into microcentrifuge tubes before 50 µl 
of 2X reaction buffer containing Dithiothreitol (DTT) was 
added to each sample. Afterwards, 5 µl of 4mM LEHD-pNA 
substrate was added to the samples and incubated at 37°C for 
2 hours before reading at 400nm in a microplate reader.  
 
Measurement of intracellular reactive oxygen species 
Intracellular ROS activity was determined using the 
fluorescent probe 2′,7′-Dichlorofluorescin diacetate 
(DCFH-DA, Sigma St Louis, USA). Briefly, cells were 
plated in 60 mm dishes and treated with IC50 of S. 
frutescens for 48 hours and thereafter collected by 
trypsinization. Cells were washed with 1X PBS and 
centrifuged at 3000 revolutions per minute (rpm). The 
resultant pellet was stained with DCFH-DA for 1 hour 
after which cells were resuspended in 500 µl of PBS and 
fluorescence was acquired with the BD Accuri 
CSampler Flow Cytometer (BD Biosciences 
Pharmingen, San Diego, CA, USA). 
 
Measurement of mitochondria membrane potential  
Flow cytometry was used to determine loss of 
mitochondrial membrane potential (MMP) following 
staining with the fluorescent dye rhodamine 123 (Sigma 
St Louis, USA). Briefly, cells were seeded at an 
appropriate density in 60 mm dishes and allowed to 
attach overnight before exposure to the IC50 
concentration of S. frutescens for 48 hours. Cells were 
collected after treatment and washed with 1X PBS, 
centrifuged at 3000 rpm for 3 minutes and the resultant 
pellets were re-suspended in 10 µm of rhodamine 123 in 
supplemented DMEM for 30 minutes. The cells were 
thereafter centrifuged at 3000 rpm for 3 minutes and 
pellets were resuspended in 500 µl PBS for measurement 




Data generated from this study was expressed as means 
± standard error of mean (SEM) of three independent 
experiments and analyzed using the GraphPad Prism 6 
software. Groups were compared using the t-test and 
level of significance was set at P ≤ 0.05. 
 
RESULTS 
S. frutescens inhibits cell viability in SKNBE(2) and 
SHSY5Y neuroblastoma cells 
In this study, the effect of the aqueous extract of S. 
frutescens on cell viability in SKNBE(2) and SHSY5Y 
neuroblastoma cells was determined using the MTT 
assay. Cells were plated in 96 well plates and exposed to 
increasing concentrations (1 to 5 mg/ml) of the extract 
for 48 hours after which MTT assays were performed. 
Results show that on both SKNBE(2) and SHSY5Y 
cells, S. frutescens induced a dose-dependent reduction 
in cell viability when compared to the control. Indeed the 
IC50 values obtained from sigmoidal plots were 2.3 
mg/ml and 2.2 mg/ml for SKNBE(2) and SHSY5Y cells 
respectively (Figure 1 A and B). Furthermore, the 
selectivity of S. frutescens to cancer cells was next 
determined. The non-tumourigenic fibroblast KMST6 
cells were exposed to concentrations of S. frutescens as 
same as those used for the neuroblastomas. Figure 1C 
shows that the KMST6 cells were less sensitive to the 
extract and at 5 mg/ml concentration cell survival was 
50.9%. Taken together these results show that whereas 
S. frutescens inhibited cell viability in the neuroblastoma 
cells, it exhibited less cytotoxic activity in the non-
cancerous KMST6 cells. 
  
S. frutescens inhibits cell survival in SKNBE(2) 
neuroblastoma cells 
The clonogenic assay was performed to determine the 
impact of S. frutescens treatment on the long-term 
survival of SKNBE(2) as it assesses the reproductive 
capacity of cells after treatment. Figure 2 shows that 
both the half IC50 (1.15 mg/ml) and IC50 (2.3 mg/ml) of 
S. frutescens significantly reduced colony formation in a 
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dose-dependent manner in SKNBE(2) cells (Figure 2 A). 
When colony areas were quantified with the control set 
at 100%, results obtained show that the colony area 
reduced to 32.1% and 7.9% for half IC50 and IC50 
respectively (Figure 2B). Together, these results suggest 





Figure1. S. frutescens inhibits cell viability cell viability in 
neuroblastoma cells. S. frutescens induced a dose-dependent 
response in (A) SKNBE(2) (B) SHSY5Y and (C) KMST6. 
Bars represent means ± SEM of three independent 
experiments performed in quadruplicate wells. *p ≤ 0.05. 
 
S. frutescens inhibits cell survival in SKNBE(2) 
neuroblastoma cells 
The clonogenic assay was performed to determine the 
impact of S. frutescens treatment on the long-term 
survival of SKNBE(2) as it assesses the reproductive 
capacity of cells after treatment. Figure 2 shows that 
both the half IC50 (1.15 mg/ml) and IC50 (2.3 mg/ml) of 
S. frutescens significantly reduced colony formation in a 
dose-dependent manner in SKNBE(2) cells (Figure 2 A). 
When colony areas were quantified with the control set 
at 100%, results obtained show that the colony area 
reduced to 32.1% and 7.9% for half IC50 and IC50 
respectively (Figure 2B). Together, these results suggest 
that S. frutescens mitigates survival of malignant 
neuroblastoma cells.  
 
S. frutescens activates Caspase-9 activity in 
neuroblastoma cells 
S. frutescens has previously been reported to induce 
cytotoxicity and inhibit cell viability in cancer cells via 
apoptosis (Chinkwo, 2005, van der Walt et al., 2016). 
Caspases   are known as the   molecular machinery that 
 
Figure 2. S. frutescens inhibits colony formation. (A) S. 
frutescens shows a dose-dependent reduction in colony 
formation in SKNBE(2) cells following staining of cells with 
crystal violet. (B) Quantification of colony area using Image 
J. Bars represent means ± SEM. *p ≤ 0.05. 
 
 
drives apoptosis and caspase-9 activation is widely 
reported to be involved in the cascade of events in the 
mitochondrial apoptotic pathway (Wang and Xu, 2005, 
Shao et al., 2014). In this study, Caspase-9 activity was 
investigated in neuroblastoma cells treated with S. 
frutescens. Results show that S. frutescens significantly 
induced apoptosis in SKNBE(2) and SHSY5Y 
neuroblastoma cells by the increase in caspase-9 activity 
when compared to treated cells (Figure 3). Altogether, 
findings from this study suggest that apoptosis is 
involved in the cytotoxicity induced by S. frutescens in 
both neuroblastoma cell lines. 
 
S. frutescens increases intracellular ROS generation in 
neuroblastoma cells 
Excessive ROS production is widely known to induce 
cytotoxicity in cells and is largely due to an imbalance 
between ROS production and intracellular antioxidant 
defence mechanisms (Schumacker, 2006). To 
understand the apoptotic mechanism induced by S. 
frutescens in SKNBE(2) and SHSY5Y neuroblastoma 
cells, the level of intracellular ROS was investigated  as 
previously described. The SKNBE(2) and SHSY5Y 
cells were treated with 2.3 and 2.2 mg/ml concentrations 
of S. frutescens respectively and stained with DCFH-
DA. Results show that S. frutescens treatment on both 
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cell lines caused a shift in fluorescence to the right when 
compared to the control, indicating increased 
accumulation of intracellular ROS (Figure 4A and B).  
 
 
Fig. 3: S. frutescens activates Caspase-9 activity. SKNBE(2) 
(A) and SHSY5Y (B) treated with 2.3 and 2.2 mg/ml of S. 
frutescens respectively for 48 hours showed a significant 
activation of Caspase-9 when expressed as fold of control. 
Each bar represents mean ± SEM.*p≤ 0.05. 
 
When the mean fluorescence intensity of treated cells 
was expressed as fold of control, SKNBE(2) and 
SHSY5Y treated cells showed an increase in 
fluorescence intensity (Figure 4 C and D). Taken 
together, these results suggest that S. frutescens 
treatment led to the accumulation of intracellular ROS in 
neuroblastoma cells and may in part contribute to the 
apoptosis observed in the cells. 
 
Figure 4. S. frutescens induces Intracellular ROS 
accumulation. Representative flow cytometric profile 
of SKNBE(2) (A) and SHSY5Y (B) treated with 2.3 and 
2.2 mg/ml of S. frutescens respectively for 48 hours. The 
black histogram shows the profile of control cells and 
coloured histogram shows the profile of treated cells. 
The mean fluorescence intensity of treated cells was 
expressed as fold of control (C) SKNBE(2) and (D) 
SHSY5Y. Each bar represents mean ± SEM. *p ≤ 0.05. 
 
S. frutescens induces loss of MMP in neuroblastoma 
cells 
Mitochondrial function is highly critical for cell 
survival, and an interruption of MMP is known to induce 
apoptosis in cells via the mitochondrial apoptotic 
pathway (Shao et al., 2014). Following exposure to S. 
frutescens, SKNBE(2) and SHSY5Y neuroblastoma 
cells were stained with the rhodamine 123 fluorescent 
probe, and MMP was measured using the flow 
cytometer. Figures 5 A and B show a reduction in 
fluorescence intensity in the S. frutescens-treated cells as 
evident by a shift in fluorescence to the left when 
compared to the control. Furthermore, the mean 
fluorescence intensity (expressed as fold of control) was 
much lower in both SKNBE(2) and SHSY5Y cells 
(Figures 5 C and D). Taken together, these results 
indicate that treatment with S. frutescens led to a 
disruption of MMP in neuroblastoma cells and might 
play a role in the cytotoxicity observed in these cells.  
 
Figure 5. S. frutescens disrupts MMP.  Flow 
cytometric assay of MMP changes detected with 
Rhodamine 123 dye in SKNBE(2) (A) and SHSY5Y (B) 
treated with 2.3 and 2.2 mg/ml of S. frutescens 
respectively for 48 hours. The change in the fluorescence 
intensity of Rhodamine 123 indicated the loss of MMP 
and the mean fluorescence intensity of treated cells were 
expressed as fold of control (C) SKNBE(2) and (D) 
SHSY5Y. Each bar represents mean± SEM. *p ≤ 0.05. 
 
S. frutescens increases intracellular ROS generation in 
neuroblastoma cells 
Excessive ROS production is widely known to induce 
cytotoxicity in cells and is largely due to an imbalance 
between ROS production and intracellular antioxidant 
defence mechanisms (Schumacker, 2006). To 
understand the apoptotic mechanism induced by S. 
frutescens in SKNBE(2) and SHSY5Y neuroblastoma 
cells, the level of intracellular ROS was investigated  as 
previously described. The SKNBE(2) and SHSY5Y 
cells were treated with 2.3 and 2.2 mg/ml concentrations 
of S. frutescens respectively and stained with DCFH-
DA. Results show that S. frutescens treatment on both 
cell lines caused a shift in fluorescence to the right when 
compared to the control, indicating increased 
accumulation of intracellular ROS (Figure 4A and B). 
When the mean fluorescence intensity of treated cells 
was expressed as fold of control, SKNBE(2) and 
SHSY5Y treated cells showed an increase in 
fluorescence intensity (Figure 4 C and D). Taken 
together, these results suggest that S. frutescens 
treatment led to the accumulation of intracellular ROS in 
neuroblastoma cells and may in part contribute to the 
apoptosis observed in the cells. 
 
S. frutescens induces loss of MMP in neuroblastoma 
cells 
Mitochondrial function is highly critical for cell 
survival, and an interruption of MMP is known to induce 
apoptosis in cells via the mitochondrial apoptotic 
pathway (Shao et al., 2014). Following exposure to S. 
frutescens, SKNBE(2) and SHSY5Y neuroblastoma 
cells were stained with the rhodamine 123 fluorescent 
probe, and MMP was measured using the flow 
cytometer. Figures 5 A and B show a reduction in 
fluorescence intensity in the S. frutescens-treated cells as  
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evident by a shift in fluorescence to the left when 
compared to the control. Furthermore, the mean 
fluorescence intensity (expressed as fold of control) was 
much lower in both SKNBE(2) and SHSY5Y cells 
(Figures 5 C and D). Taken together, these results 
indicate that treatment with S. frutescens led to a 
disruption of MMP in neuroblastoma cells and might 
play a role in the cytotoxicity observed in these cells.  
 
DISCUSSION 
S. frutescens is an indigenous plant of South Africa and 
has been of benefit to many cultures with its origin 
linked to the Khoi people of South Africa. It has been 
used in ancient times for various disease conditions 
including internal cancers (Van Wyk and Albrecht, 
2008). Previous studies have confirmed that this plant 
has potent anti-cancer properties in breast, ovarian, 
oesophageal, cervical and leukaemia cancerous cells 
(Tai et al., 2004, Chinkwo, 2005, Stander et al., 2009, 
Skerman et al., 2011). In the present study, the cytotoxic 
effect of S. frutescens was investigated in SKNBE(2) 
and SHSY5Y neuroblastoma cells and results obtained 
show that the aqueous extract of this plant induced dose-
dependent cytotoxicity in both these cell lines but was 
selectively less sensitive to the non-cancerous KMST6 
cells. Findings from the clonogenic assay showed that S. 
frutescens inhibited cell proliferation and survival as 
evident by the reduction in colony area in the treated 
cells when compared to the control, thus suggesting a 
loss of reproductive capacity after treatment. These 
findings are supportive of the cytotoxicity results.  
Apoptosis, or programmed cell death, plays an essential 
role in regulating a broad range of biological processes, 
such as cell differentiation and proliferation, 
development, immunity, and tissue homeostasis and 
Fig.4: S. frutescens induces Intracellular ROS accumulation. 
Representative flow cytometric profile of SKNBE(2) (A) and 
SHSY5Y (B) treated with 2.3 and 2.2 mg/ml of S. frutescens 
respectively for 48 hours. The black histogram shows the 
profile of control cells and coloured histogram shows the 
profile of treated cells. The mean fluorescence intensity of 
treated cells was expressed as fold of control (C) SKNBE(2) 
and (D) SHSY5Y. Each bar represents mean ± SEM. *p ≤ 
0.05. Fig.4: S. frutescens induces Intracellular ROS 
accumulation. Representative flow cytometric profile of 
SKNBE(2) (A) and SHSY5Y (B) treated with 2.3 and 2.2 
mg/ml of S. frutescens respectively for 48 hours. The black 
histogram shows the profile of control cells and coloured 
histogram shows the profile of treated cells. The mean 
fluorescence intensity of treated cells was expressed as fold of 
control (C) SKNBE(2) and (D) SHSY5Y. Each bar represents 
mean ± SEM. *p ≤ 0.05. 
Fig. 5: S. frutescens disrupts MMP.  Flow cytometric assay of 
MMP changes detected with Rhodamine 123 dye in 
SKNBE(2) (A) and SHSY5Y (B) treated with 2.3 and 2.2 
mg/ml of S. frutescens respectively for 48 hours. The change 
in the fluorescence intensity of Rhodamine 123 indicated the 
loss of MMP and the mean fluorescence intensity of treated 
cells were expressed as fold of control (C) SKNBE(2) and (D) 
SHSY5Y. Each bar represents mean± SEM. *p ≤ 0.05. 
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dysregulation of apoptosis is associated with a variety of 
human diseases, including cancer, autoimmune diseases, 
infections, and neurodegenerative diseases (Fuchs and 
Steller, 2011, Han and Ravichandran, 2011, Portt et al., 
2011). Apoptosis is the most important therapeutic target 
and the most common mechanism by which 
chemotherapeutic agents induce death in cancer cells to 
eradicate tumour tissue. The induction of apoptosis is 
regarded as the most effective strategy for eliminating 
cancer cells (Pore et al., 2013, Signore et al., 2013). The 
results of the present study show that S. frutescens 
induced apoptosis in both neuroblastoma cell lines 
possibly via the mechanisms of loss of MMP and 
accumulation of ROS both of which have been reported 
to play a role in the induction of apoptosis in cancer cells. 
The findings from this study align with previous studies 
which showed that the observed death of cancer cells 
following treatment with S. frutescens was mediated via 
apoptotic pathways (Stander et al., 2009, Skerman et al., 
2011, van der Walt et al., 2016). The loss of MMP 
observed in both the SKNBE(2) and SHSY5Y cells in 
this study following treatment with S. frutescens, has 
been linked to cytotoxicity and apoptosis in cancer 
cells (Shao et al., 2014). 
ROS are strongly involved in the regulation of many 
cellular functions and a moderate rise in ROS could 
result in enhanced cell growth and proliferation. 
However, overproduction of ROS beyond levels which 
endogenous antioxidants can cope with, will result in 
oxidative stress and cell death (Trachootham et al., 
2009). Most tumour cells have been reported to contain 
high levels of ROS and as such rely on endogenous 
antioxidants to regulate redox balance in order to 
continue promoting cell survival (Wang et al., 2017). 
Thus, a fragile imbalance in ROS-antioxidant levels 
could be a possible target for anti-cancer agents (Raj 
et al., 2011). Medicinal plants and plant-derived 
natural products have been previously reported to 
induce cytotoxicity by promoting oxidative stress in 
cancer cells and depleting endogenous antioxidants 
(Srinivas et al., 2004, Badmus et al., 2015). In the 
current study, treatment with S. frutescens resulted in 
the accumulation of intracellular ROS in SKNBE(2) 
and SHSY5Y neuroblastoma cells, which could 
possibly have contributed to the observed cytotoxicity. 
Furthermore, an increase in ROS accumulation could 
trigger a disruption in mitochondrial function 
(Ishikawa et al., 2008).  
The biological activity of S. frutescens has previously 
been attributed to its chemical composition including its 
large amounts of amino acids (notably l-arginine and l-
canavanine), pinitol, flavonol glycosides and 
triterpenoid saponins (Moshe et al., 1998, Van Wyk and 
Albrecht, 2008, Shaik et al., 2011). The presence of the 
compound l-canavanine and its major metabolite 
canaline in S. frutescens could be among the contributing 
factors to its in vitro anti-proliferative and apoptotic 
activity (Chinkwo 2005). Both l-canavanine and 
canaline have previously been reported to exert anti-
cancer properties (Tai et al., 2004).  
 
CONCLUSION 
This study investigated the cytotoxic and apoptosis-
inducing effects of S. frutescens in SKNBE(2) and 
SHSY5Y neuroblastoma cells. Findings show S. 
frutescens differentially induced cytotoxicity on 
cancerous and non-cancerous cells and the underlying 
mechanism was associated with apoptosis mediated via 
the ability of this plant extract to increase the 
accumulation of ROS and a loss of MMP in these cells. 
Studies to isolate the bioactive components present in 
the aqueous extract of S. frutescens responsible for 
eliciting the reported effects need to be done. In addition, 
more molecular studies to elucidate other possible 
mechanisms involved in S. frutescens-induced cell death 
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